HERBAL COMBINATIONAL MEDICATION OF ASLUSSOOS (GLYCYRRHIZA GLABRA) CONTAINING GLYCYRRHIZIC ACID INHIBITS CHRONIC BRONCHITIS (MUZMIN ILTEHAB SHO’B)- A POTENTIAL PHARMACOLOGICAL APPLICATION WITH MECHANISTIC INSIGHT-A RESEARCH ARTICLE

Authors

  • Dr. Shaikh Mohd. Wajid Associate Professor & HOD, Dept. of Ilaj bit Tadbeer, Markaz Unani Medical College and Hospital, Kozhikode, Kerala (India) Author
  • Dr. Shaikh Mudassar Shaikh Altaf Maniyar Lecturer, Dept. of Moalejat, Al Ameen Unani Medical college & Hospital, Malegaon Dist: Nasik (India) Author
  • Dr. Daniya Wazeef Momin Associate Professor & HOD, Dept. of Amraz-e-Atfal wa Naumaulood, Dr. M. I. J. Tibbia Unani Medical College & H. A. R. Kalsekar Hospital, Mumbai (India) Author
  • Dr. Khan Sumayya Abdul Razzak Assistant Professor, Dept. of Amraz-e-Ain Anf Halaque wa Asnan, Dr. M. I. J. Tibbia Unani Medical College & H. A. R. Kalsekar Hospital, Mumbai (India) Author
  • Dr. Ansari Mohd. Danish Mohd. Nasim PG Scholar, Dept of Ilm-ul-Jarahat (Surgery), National Institute of Unani Medicine, Bengaluru – Karnataka (India) Author
  • Gazala Shamim Rashid Ahmed Professor & HOD, Dept. of Amraz-e-Atfal wa Naumaulood , Al Ameen Unani Medical College & Hospital, Malegaon Dist: Nasik. MH. (India) Author

DOI:

https://doi.org/10.48047/g9g7py82

Keywords:

Chronic bronchitis, Muzmin Iltehab Sho’b, Aslussoos, Unani medicine, COPD, Pulmonary function test, Herbal therapy

Abstract

Chronic bronchitis, a major component of chronic obstructive pulmonary disease, is characterized by persistent cough, excessive mucus secretion, and airflow limitation. Conventional therapies provide symptomatic relief but are often associated with adverse effects and limited long-term benefits. Unani medicine describes this condition as a disorder of Sue Mizaj Ratab of the lungs with excessive ratoobat (secretions). The present open randomized clinical study was designed to evaluate the therapeutic efficacy and safety of Aslussoos, a well-known Unani drug possessing expectorant, anti-inflammatory, and demulcent properties, in patients of chronic bronchitis. Thirty clinically diagnosed patients aged 40–60 years were enrolled and treated with Sufoof-e-Aslussoos (3 g twice daily) for 30 days. Clinical assessment and laboratory investigations, including haematological parameters and pulmonary function tests, were conducted before and after treatment. Statistical analysis using paired t-test revealed highly significant improvement (p<0.0001) in haematological indices, reduction in inflammatory markers, and marked enhancement in pulmonary function parameters such as FEV₁, FEV₁/FVC ratio, and peak expiratory flow rate. The study concludes that Aslussoos is an effective, safe, and economical therapeutic option for the management of chronic bronchitis, supporting its traditional use with modern scientific evidence.

Downloads

Download data is not yet available.

References

Pride NB, Stockley RA. Chronic obstructive pulmonary disease. In: Oxford Textbook of Medicine. Vol. II, 3rd ed. Oxford: Oxford University Press; 1996. pp. 766–778.

Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. MMWR Surveillance Summaries. 2002;51(6):1–16.

Tabri AAM. Molaejat Buqratiyah (Urdu translation by CCRUM). Vol. II. New Delhi: Ministry of Health and Family Welfare; 1997. pp. 468–469.

Di Stefano A, Maestrelli P, Roggeri A, Turato G, Calabrò S, Potena A. Severity of airflow limitation is associated with severity of airway inflammation in smokers. American Journal of Respiratory and Critical Care Medicine. 1998;158:1277–1285.

Vestbo J, Prescott E, Lange P; Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV₁ decline and chronic obstructive pulmonary disease morbidity. American Journal of Respiratory and Critical Care Medicine. 1996;153:1530–1535.

Mohan H. Textbook of Pathology. 5th ed. New Delhi: Jaypee Brothers Medical Publishers; 2005. pp. 485–487.

Cotran RS, Kumar V, Collins T. Robbins Pathologic Basis of Disease. 6th ed. Singapore: W.B. Saunders Company; 2000. pp. 707–717.

Kumar V, Cotran RS, Robbins SL. Basic Pathology. 6th ed. Singapore: Harcourt Asia Pte Ltd; 1997. pp. 397, 402–403.

Dey NC, Dey TK. A Textbook of Pathology. 15th ed. Kolkata: New Central Book Agency (P) Ltd; 2002. p. 17.5.

Deodhare SG. General Pathology & Pathology of Systems. Revised 6th ed. Mumbai: Popular Prakashan; 2002. Vol. II, pp. 1065, 1509–1513.

Matsuba K, Wright JL, Wiggs BR, Pare PD, Hogg JC. Changes in airway structure associated with reduced FEV₁. European Respiratory Journal. 1989;2:834–839.

Lamb D, McLean A, Gillooly M, Warren PM, Gould GA, MacNee W. Relation between distal airspace size, bronchiolar attachments, and lung function. Thorax. 1993;48:1012–1017.

O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2001;164:770–777.

Rodriguez-Roisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary disease. European Respiratory Monograph. 1998;3:107–126.

McLean A, Warren PM, Gillooly M, MacNee W, Lamb D. Microscopic and macroscopic measurements of emphysema: relation to carbon monoxide gas transfer. Thorax. 1992;47:144–149.

MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease: Part two. American Journal of Respiratory and Critical Care Medicine. 1994;150:1158–1168.

Biernacki W, Flenley DC, Muir AL, MacNee W. Pulmonary hypertension and right ventricular function in patients with COPD. Chest. 1988;94:1169–1175.

William MN. ABC of chronic obstructive pulmonary disease: Pathology, pathogenesis and pathophysiology. BMJ. 2006;332:1202–1204.

Razi AMBZ. Kitab Al-Mansoori (Urdu translation by CCRUM). New Delhi: Ministry of Health and Family Welfare, Government of India; 1991. pp. 350–351.

Jeelani G. Makhzan-e-Hikmat. Vol. II. New Delhi: Aijaz Publishing House; 1994. pp. 379–381.

Downloads

Published

2024-12-31

Issue

Vol. 53 No. 03 (2024): Year 2024, Volume 53, Issue 3

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

HERBAL COMBINATIONAL MEDICATION OF ASLUSSOOS (GLYCYRRHIZA GLABRA) CONTAINING GLYCYRRHIZIC ACID INHIBITS CHRONIC BRONCHITIS (MUZMIN ILTEHAB SHO’B)- A POTENTIAL PHARMACOLOGICAL APPLICATION WITH MECHANISTIC INSIGHT-A RESEARCH ARTICLE (S. M. Wajid, S. M. S. A. Maniyar, D. W. Momin, K. S. A. Razzak, A. M. D. M. Nasim, & G. S. R. Ahmed , Trans.). (2024). Cuestiones De Fisioterapia, 53(03), 5376-5390. https://doi.org/10.48047/g9g7py82